Thromboembolism in Patients with Aortic Porcine Bioprostheses
Thromboembolism was prospectively studied in 215 patients who survived aortic valve replacement with porcine bioprostheses. All patients were anticoagulated with warfarin sodium during the first 3 postoperative months. Thereafter, 80 patients received aspirin (325 or 650 mg per day) and 135 received...
Gespeichert in:
| Veröffentlicht in: | The Annals of thoracic surgery 1985-09, Vol.40 (3), p.229-233 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 233 |
|---|---|
| container_issue | 3 |
| container_start_page | 229 |
| container_title | The Annals of thoracic surgery |
| container_volume | 40 |
| creator | David, Tirone E. Ho, Walter I.C. Christakis, George T. |
| description | Thromboembolism was prospectively studied in 215 patients who survived aortic valve replacement with porcine bioprostheses. All patients were anticoagulated with warfarin sodium during the first 3 postoperative months. Thereafter, 80 patients received aspirin (325 or 650 mg per day) and 135 received no antiplatelet or anticoagulant drugs. The two groups of patients were similar. Thromboembolic complications were carefully searched for during the follow-up interviews. Patients were removed from the study after a thromboembolic event unless there was no change in their management.
The follow-up ranged from 6 to 80 months (mean, 36 months). The linearized thromboembolic rate in patients on a regimen of aspirin was 1.3% per patient-year and in patients not taking aspirin, 5.2% per patient-year (
p < 0.02). Replacement of the ascending aorta and patch enlargement of the aortic annulus with a Teflon graft were identified as significant risk factors for thromboembolism in patients with aortic porcine bioprostheses.
These findings indicate that patients with aortic porcine bioprostheses should receive aspirin, especially if they also had replacement of the ascending aorta or patch enlargement of the aortic annulus with a Teflon graft. |
| doi_str_mv | 10.1016/S0003-4975(10)60033-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76372402</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0003497510600331</els_id><sourcerecordid>76372402</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-921352db64e01f9e6ebe54f1fef134521d47cab79d926b7a1f794a68c7cab7123</originalsourceid><addsrcrecordid>eNqFkEtLAzEQgIMotVZ_QmEPInpYzSTZ3eYgUosvKFiwnkM2O0sj-9Bkq_jvzbalVw8hzMw3Dz5CxkCvgUJ680Yp5bGQWXIJ9CoNAY_hgAwhSVicskQekuEeOSYn3n-EkIXygAwE5ZkEMSS3y5Vr67zF8Crr68g20UJ3FpvORz-2W0XT1nXWRIvWGdtgdG_bT9f6boUe_Sk5KnXl8Wz3j8j748Ny9hzPX59eZtN5bAQTXSwZ8IQVeSqQQikxxRwTUUKJJXCRMChEZnSeyUKyNM80lJkUOp2YTRYYH5GL7dyw-muNvlO19QarSjfYrr3KUp4xQXsw2YIm3OgdlurT2Vq7XwVU9drURpvqnfSpjTYFoW-8W7DOayz2XTtPoX6-q2tvdFU63Rjr95hkHCa8x-62GAYZ3xad8iaoNFhYh6ZTRWv_OeQPB6KIzQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76372402</pqid></control><display><type>article</type><title>Thromboembolism in Patients with Aortic Porcine Bioprostheses</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>David, Tirone E. ; Ho, Walter I.C. ; Christakis, George T.</creator><creatorcontrib>David, Tirone E. ; Ho, Walter I.C. ; Christakis, George T.</creatorcontrib><description>Thromboembolism was prospectively studied in 215 patients who survived aortic valve replacement with porcine bioprostheses. All patients were anticoagulated with warfarin sodium during the first 3 postoperative months. Thereafter, 80 patients received aspirin (325 or 650 mg per day) and 135 received no antiplatelet or anticoagulant drugs. The two groups of patients were similar. Thromboembolic complications were carefully searched for during the follow-up interviews. Patients were removed from the study after a thromboembolic event unless there was no change in their management.
The follow-up ranged from 6 to 80 months (mean, 36 months). The linearized thromboembolic rate in patients on a regimen of aspirin was 1.3% per patient-year and in patients not taking aspirin, 5.2% per patient-year (
p < 0.02). Replacement of the ascending aorta and patch enlargement of the aortic annulus with a Teflon graft were identified as significant risk factors for thromboembolism in patients with aortic porcine bioprostheses.
These findings indicate that patients with aortic porcine bioprostheses should receive aspirin, especially if they also had replacement of the ascending aorta or patch enlargement of the aortic annulus with a Teflon graft.</description><identifier>ISSN: 0003-4975</identifier><identifier>EISSN: 1552-6259</identifier><identifier>DOI: 10.1016/S0003-4975(10)60033-1</identifier><identifier>PMID: 4037914</identifier><identifier>CODEN: ATHSAK</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aorta - surgery ; Aortic Valve ; Aspirin - therapeutic use ; Biological and medical sciences ; Bioprosthesis - adverse effects ; Blood Vessel Prosthesis ; Cardiology. Vascular system ; Endocardial and cardiac valvular diseases ; Female ; Follow-Up Studies ; Heart ; Heart Valve Prosthesis - adverse effects ; Humans ; Male ; Medical sciences ; Middle Aged ; Polytetrafluoroethylene ; Postoperative Complications - etiology ; Prospective Studies ; Risk ; Thromboembolism - etiology ; Thromboembolism - prevention & control ; Time Factors ; Warfarin - therapeutic use</subject><ispartof>The Annals of thoracic surgery, 1985-09, Vol.40 (3), p.229-233</ispartof><rights>1985 The Society of Thoracic Surgeons</rights><rights>1985 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-921352db64e01f9e6ebe54f1fef134521d47cab79d926b7a1f794a68c7cab7123</citedby><cites>FETCH-LOGICAL-c424t-921352db64e01f9e6ebe54f1fef134521d47cab79d926b7a1f794a68c7cab7123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23911,23912,25120,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9231834$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4037914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>David, Tirone E.</creatorcontrib><creatorcontrib>Ho, Walter I.C.</creatorcontrib><creatorcontrib>Christakis, George T.</creatorcontrib><title>Thromboembolism in Patients with Aortic Porcine Bioprostheses</title><title>The Annals of thoracic surgery</title><addtitle>Ann Thorac Surg</addtitle><description>Thromboembolism was prospectively studied in 215 patients who survived aortic valve replacement with porcine bioprostheses. All patients were anticoagulated with warfarin sodium during the first 3 postoperative months. Thereafter, 80 patients received aspirin (325 or 650 mg per day) and 135 received no antiplatelet or anticoagulant drugs. The two groups of patients were similar. Thromboembolic complications were carefully searched for during the follow-up interviews. Patients were removed from the study after a thromboembolic event unless there was no change in their management.
The follow-up ranged from 6 to 80 months (mean, 36 months). The linearized thromboembolic rate in patients on a regimen of aspirin was 1.3% per patient-year and in patients not taking aspirin, 5.2% per patient-year (
p < 0.02). Replacement of the ascending aorta and patch enlargement of the aortic annulus with a Teflon graft were identified as significant risk factors for thromboembolism in patients with aortic porcine bioprostheses.
These findings indicate that patients with aortic porcine bioprostheses should receive aspirin, especially if they also had replacement of the ascending aorta or patch enlargement of the aortic annulus with a Teflon graft.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aorta - surgery</subject><subject>Aortic Valve</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bioprosthesis - adverse effects</subject><subject>Blood Vessel Prosthesis</subject><subject>Cardiology. Vascular system</subject><subject>Endocardial and cardiac valvular diseases</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart</subject><subject>Heart Valve Prosthesis - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Polytetrafluoroethylene</subject><subject>Postoperative Complications - etiology</subject><subject>Prospective Studies</subject><subject>Risk</subject><subject>Thromboembolism - etiology</subject><subject>Thromboembolism - prevention & control</subject><subject>Time Factors</subject><subject>Warfarin - therapeutic use</subject><issn>0003-4975</issn><issn>1552-6259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEQgIMotVZ_QmEPInpYzSTZ3eYgUosvKFiwnkM2O0sj-9Bkq_jvzbalVw8hzMw3Dz5CxkCvgUJ680Yp5bGQWXIJ9CoNAY_hgAwhSVicskQekuEeOSYn3n-EkIXygAwE5ZkEMSS3y5Vr67zF8Crr68g20UJ3FpvORz-2W0XT1nXWRIvWGdtgdG_bT9f6boUe_Sk5KnXl8Wz3j8j748Ny9hzPX59eZtN5bAQTXSwZ8IQVeSqQQikxxRwTUUKJJXCRMChEZnSeyUKyNM80lJkUOp2YTRYYH5GL7dyw-muNvlO19QarSjfYrr3KUp4xQXsw2YIm3OgdlurT2Vq7XwVU9drURpvqnfSpjTYFoW-8W7DOayz2XTtPoX6-q2tvdFU63Rjr95hkHCa8x-62GAYZ3xad8iaoNFhYh6ZTRWv_OeQPB6KIzQ</recordid><startdate>198509</startdate><enddate>198509</enddate><creator>David, Tirone E.</creator><creator>Ho, Walter I.C.</creator><creator>Christakis, George T.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198509</creationdate><title>Thromboembolism in Patients with Aortic Porcine Bioprostheses</title><author>David, Tirone E. ; Ho, Walter I.C. ; Christakis, George T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-921352db64e01f9e6ebe54f1fef134521d47cab79d926b7a1f794a68c7cab7123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aorta - surgery</topic><topic>Aortic Valve</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bioprosthesis - adverse effects</topic><topic>Blood Vessel Prosthesis</topic><topic>Cardiology. Vascular system</topic><topic>Endocardial and cardiac valvular diseases</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart</topic><topic>Heart Valve Prosthesis - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Polytetrafluoroethylene</topic><topic>Postoperative Complications - etiology</topic><topic>Prospective Studies</topic><topic>Risk</topic><topic>Thromboembolism - etiology</topic><topic>Thromboembolism - prevention & control</topic><topic>Time Factors</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>David, Tirone E.</creatorcontrib><creatorcontrib>Ho, Walter I.C.</creatorcontrib><creatorcontrib>Christakis, George T.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>David, Tirone E.</au><au>Ho, Walter I.C.</au><au>Christakis, George T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thromboembolism in Patients with Aortic Porcine Bioprostheses</atitle><jtitle>The Annals of thoracic surgery</jtitle><addtitle>Ann Thorac Surg</addtitle><date>1985-09</date><risdate>1985</risdate><volume>40</volume><issue>3</issue><spage>229</spage><epage>233</epage><pages>229-233</pages><issn>0003-4975</issn><eissn>1552-6259</eissn><coden>ATHSAK</coden><abstract>Thromboembolism was prospectively studied in 215 patients who survived aortic valve replacement with porcine bioprostheses. All patients were anticoagulated with warfarin sodium during the first 3 postoperative months. Thereafter, 80 patients received aspirin (325 or 650 mg per day) and 135 received no antiplatelet or anticoagulant drugs. The two groups of patients were similar. Thromboembolic complications were carefully searched for during the follow-up interviews. Patients were removed from the study after a thromboembolic event unless there was no change in their management.
The follow-up ranged from 6 to 80 months (mean, 36 months). The linearized thromboembolic rate in patients on a regimen of aspirin was 1.3% per patient-year and in patients not taking aspirin, 5.2% per patient-year (
p < 0.02). Replacement of the ascending aorta and patch enlargement of the aortic annulus with a Teflon graft were identified as significant risk factors for thromboembolism in patients with aortic porcine bioprostheses.
These findings indicate that patients with aortic porcine bioprostheses should receive aspirin, especially if they also had replacement of the ascending aorta or patch enlargement of the aortic annulus with a Teflon graft.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>4037914</pmid><doi>10.1016/S0003-4975(10)60033-1</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4975 |
| ispartof | The Annals of thoracic surgery, 1985-09, Vol.40 (3), p.229-233 |
| issn | 0003-4975 1552-6259 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76372402 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aorta - surgery Aortic Valve Aspirin - therapeutic use Biological and medical sciences Bioprosthesis - adverse effects Blood Vessel Prosthesis Cardiology. Vascular system Endocardial and cardiac valvular diseases Female Follow-Up Studies Heart Heart Valve Prosthesis - adverse effects Humans Male Medical sciences Middle Aged Polytetrafluoroethylene Postoperative Complications - etiology Prospective Studies Risk Thromboembolism - etiology Thromboembolism - prevention & control Time Factors Warfarin - therapeutic use |
| title | Thromboembolism in Patients with Aortic Porcine Bioprostheses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T09%3A45%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thromboembolism%20in%20Patients%20with%20Aortic%20Porcine%20Bioprostheses&rft.jtitle=The%20Annals%20of%20thoracic%20surgery&rft.au=David,%20Tirone%20E.&rft.date=1985-09&rft.volume=40&rft.issue=3&rft.spage=229&rft.epage=233&rft.pages=229-233&rft.issn=0003-4975&rft.eissn=1552-6259&rft.coden=ATHSAK&rft_id=info:doi/10.1016/S0003-4975(10)60033-1&rft_dat=%3Cproquest_cross%3E76372402%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76372402&rft_id=info:pmid/4037914&rft_els_id=S0003497510600331&rfr_iscdi=true |